Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior
It is reported that dopamine D2/D3 agonists elicit dose-dependent yawning behavior in rats, resulting in an inverted U-shaped dose-response curve.
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
The results suggest that the cortical selectivity in the release of catecholamines, dopamine in particular, induced by the cannabinoid antagonist SR141716A, its procholinergic properties, together with its mild stimulatory effects on serotonin and norepinephrine efflux make similar compounds unique candidates for the treatment of psychosis, affective and cognitive disorders.
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation
- P. Svenningsson, E. Tzavara, P. Greengard
- Psychology, BiologyThe Journal of Neuroscience
- 11 April 2007
5-HT6 receptor stimulation may be a mechanism initiating some of the biochemical and behavioral outcomes of 5-HT reuptake inhibitors, such as fluoxetine, which indicates that selective 5- HT6 receptor agonists may represent a novel antidepressant drug class.
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac)
- P. Svenningsson, E. Tzavara, J. Witkin, A. Fienberg, G. Nomikos, P. Greengard
- Biology, PsychologyProceedings of the National Academy of Sciences…
- 5 March 2002
It is shown that, in vivo, fluoxetine, given either acutely or chronically, regulates the phosphorylation state of dopamine- and cAMP-regulated phosphoprotein of Mr 32,000 (DARPP-32) at multiple sites in prefrontal cortex, hippocampus, and striatum.
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
These results demonstrate the broad preclinical efficacy of LY404039 across multiple animal models of antipsychotic and anxiolytic efficacy and provides a novel mechanism for the treatment of psychiatric disorders that may be associated with improved efficacy and reduced incidence of undesirable side effects.
Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine.
- P. Terry, J. Witkin, J. Katz
- Chemistry, BiologyThe Journal of pharmacology and experimental…
- 1 September 1994
D dopamine D-2 agonists, including quinpirole and fenoldopam, produced very limited partial substitution in substituting for cocaine, while other drugs examined for their efficacies failed to produce any cocaine-appropriate responding.
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders
Mood disorders: regulation by metabotropic glutamate receptors.
Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice
- Xia Li, A. Need, M. Baez, J. Witkin
- Biology, PsychologyJournal of Pharmacology and Experimental…
- 1 October 2006
The hypothesis that mGlu5 receptor antagonism is associated with antidepressant-like effects is substantiated and may not only provide a novel approach to the therapeutic management of depressive disorders but also may be useful in the augmentation of effects of traditional antidepressant agents.
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine
It was shown that, consistent with its cortical procholinergic and catecholamine-enhancing profile, atomoxetine significantly ameliorated performance in the object recognition test and the radial arm-maze test, and was dependent upon norepinephrine α-1 and/or dopamine D1 receptor activation.